• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

How Stakeholders Should Push Digital Health Services to Fight COVID-19

Share:

April 7, 2020

German-based Ralf Jahns, MD at Research2Guidance, explains the role of different stakeholders in fighting COVID-19.

The coronavirus is spreading around the world exponentially. Governments, healthcare providers, and businesses are introducing drastic measures to slow down the spreading of the virus.

There is a strong belief among digital health providers that their services can be of great help now. There are already more than 800 million users of digital health services globally, including symptom checkers, mental health, digital therapeutics, telehealth, fitness solutions, to name just a few segments that provide their services remotely. Providing remote care to ease the pressure on healthcare systems is what is needed now.

Digital health solutions can be effectively used throughout the entire coronavirus patient ‘lifecycle’, from triage and self-testing to quarantine and post-quarantine management. Companies are currently rushing to expand their service offerings to support the management of the COVID-19 pandemic. All industry stakeholders should act quickly to overcome barriers for a wide implementation push of digital solutions.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

There are three groups of stakeholders which are best positioned to make digital health services offerings an important piece in the puzzle to fight COVID-19. Time matters a lot. All stakeholders should focus on using what is already available on the market. Building ecosystems of existing solutions that support all stages of the coronavirus patient’s ‘lifecycle’ might be more appropriate than developing something from scratch.

First line stakeholders, such as telehealth providers, are already reporting a strong increase in the use of their services. Furthermore the second line stakeholders, such as digital therapeutics companies, are expanding their services to meet the demand from quarantined patients. Every day there is a new announcement of a COVID-19 related offering from digital diabetes, cardiovascular or digital weight loss service providers. Enablers are now asked to quickly select, promote, and apply these services to their customers, members, employees and populations.

Read more here

Source: Mobihealth News

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Novus Finalizes Acquisition of Anelixis to Further Develop AT-1501Novus Finalizes Acquisition of Anelixis to Further Develop AT-1501
  • Get Ready for the Future of Mobile Medical Imaging: Modular Devices Acquires Interim Diagnostic Imaging!Get Ready for the Future of Mobile Medical Imaging: Modular Devices Acquires Interim Diagnostic Imaging!
  • Huron Capital Completes Acquisition of Lab CraftersHuron Capital Completes Acquisition of Lab Crafters
  • Amgen, Astellas to pay government nearly $125M to resolve copay kickback allegationsAmgen, Astellas to pay government nearly $125M to resolve copay kickback allegations
  • Zepp Health Unveils Latest Smartwatch OS, Blood Pressure Measurement FeatureZepp Health Unveils Latest Smartwatch OS, Blood Pressure Measurement Feature
  • Mammoth Lands 2 Major Partnerships to Use CRISPR to Solve COVID19 Testing Shortage, At ScaleMammoth Lands 2 Major Partnerships to Use CRISPR to Solve COVID19 Testing Shortage, At Scale
  • CMAB Biopharma and BJ Bioscience Establish an Exclusive Strategic PartnershipCMAB Biopharma and BJ Bioscience Establish an Exclusive Strategic Partnership
  • Shionogi Buys Qpex Biopharma for $140M, Expands Antimicrobial PipelineShionogi Buys Qpex Biopharma for $140M, Expands Antimicrobial Pipeline

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications